Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 12:30:11 2026-03-13 pm EDT			5-day change	1st Jan Change
121.36 ^CHF	+0.43%		-2.77%	+10.73%

Mar. 13	Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa	CI
Mar. 13	Novartis Gets FDA Approval for Cosentyx in Pediatric Patients	MT

Novartis Ag Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025

Published on 02/04/2026 at 09:26 am EST

S&P Capital IQ

NOVARTIS AG

+0.43%

Novartis AG reported impairment charges for the fourth quarter ended December 31, 2025. For the quarter, the company reported property, plant and equipment impairment charges of USD 9 million, compared with USD 36 million reported for the same period a year ago. Intangible assets impairment charges were USD 367 million, compared with USD 428 million reported for the same period a year ago.

Latest news about Novartis AG

Mar. 13	Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa	CI
Mar. 13	Novartis Gets FDA Approval for Cosentyx in Pediatric Patients	MT
Mar. 13	Novartis Cosentyx(R) receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa	DJ
Mar. 12	Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research	RE
Mar. 12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
Mar. 12	Ipsen Announces Executive Changes	CI
Mar. 10	Swiss stocks - Factors to watch on March 10	RE
Mar. 09	Global drugmakers rush to boost US presence as tariff threat looms	RE
Mar. 09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update	DJ
Mar. 09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study	DJ
Mar. 09	UBS keeps CEO's pay steady at $19 million as regulatory changes loom	RE
Mar. 09	Berenberg Notes Novartis 'Fully Valued' After FY25 Report Review; Price Target Up	MT
Mar. 09	UBS boss Ermotti's pay stays at $19.1 million in 2025	RE
Mar. 06	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT
Mar. 06	Novartis AG Approves Board and Committee Appointments	CI

Chart Novartis AG

Duration

Period

NOVN: Dynamic Chart

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Apr. 28 - Earnings release - Q1 2026

More about the company